Posted in | News | MEMS - NEMS | Nanoelectronics

CopyTele Receives New Patents Pertaining to Nano Field Emission and E-Paper Electrophoretic Displays

CopyTele, Inc. (“CTI”), a company specializing in patent monetization and patent assertion, today announced that it has been awarded two new display patents from the United States Patent and Trademark Office: U.S. Patent No. 8,519,944; and U.S. Pat No. 8,469,761.

The ’944 patent pertains to CTI’s E-Paper® Electrophoretic Display technologies, and covers improvements in the resolution, contrast and response time for the generation of images using a dual particle system. The ’761 patent pertains to CTI’s Nano Field Emission Display (“nFED“) technologies, and covers a special process to reduce potential heat damage during the manufacturing process. CTI now has 14 U.S. patents in its electrophoretic display arsenal of patents, and 24 U.S. patents in its nFED arsenal of patents.

On January 28, 2013, CTI filed a lawsuit in the U.S. District Court for the Northern District of California against AU Optronics Corp. and E Ink Holdings in connection with CTI’s E-Paper® Electrophoretic Display, and Nano Field Emission Display patents, which lawsuit shall be adjudicated via arbitration.

Since announcing its new business model in October of 2012, CopyTele now has 22 active lawsuits across 5 patented technology areas, including: E-Paper Electrophoretic Displays; Nano Field Emission Displays; Key Based Web Conferencing Encryption; J-Channel Window Frame Construction; and Loyalty Conversion Systems.

About CopyTele, Inc.

CopyTele develops and acquires patented technologies for the purposes of patent monetization and patent assertion. The company currently has 6 patent portfolios in the areas of Key Based Web Conferencing Encryption, E-Paper® Electrophoretic Displays, Nano Field Emission Displays (“nFED”), Micro Electro Mechanical Systems Displays (“MEMS”), Loyalty Point Conversion Systems, and J-Channel Window Frame Construction. Additional information is available at www.CTIpatents.com.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.